KRAS and non-small cell lung carcinoma: Accumulating pieces of evidence report that the KRAS G12C inhibitors such as Sotorasib (AMG 510), ARS-1620, and Adagrasib (MRTX849) are becoming resistant in non-small-cell-lung-cancer (NSCLC) and colorectal-cancer (CRC) patients [44,45].